Zytiga (Abiraterone) Can Stop Prostate Cancer Before Surgery
A new research has discovered that Zytiga (Abiraterone), used in treating advanced prostate cancer can still help to shrink the tumor in the early stages before surgery is performed. This is to be a new presentation to the annual meeting of the American Society of Clinical Oncology (ASCO) in June, 2012.
This new study was conducted on some men and the findings from one-third showed that adding the novel drug in combination with the traditional hormone therapy treatment produces a great relieving result that eliminates high-risk localized prostate cancer before surgery. The following are further details on this new research:
A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery.
Adding Zytiga (abiraterone) to conventional hormonal treatments eliminated or nearly eliminated the prostate cancer in one-third of men with this often-lethal form, according to new research to be presented at next month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
“This is one of the first — if not the first — study to show that you can make prostate cancer in the prostate gland itself disappear in a reproducible number of patients,” ASCO official Dr. Nicholas Vogelzang said at a Wednesday press conference.
Commenting on the findings, Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, said, “This is exciting. It’s a novel way to eliminate cancer before surgery.”
However, Brooks, who was not involved in the study, cautioned that the findings were still preliminary and need further investigation.
Trying to shrink a tumor with chemotherapy and/or radiation before surgery is standard for other types of cancer, such as breast or colon, but hasn’t to date shown a benefit in prostate cancer, study author Dr. Mary-Ellen Taplin, associate professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute in Boston, explained at the news conference.
Localized high-risk prostate cancer, which is defined as prostate cancer in men with a prostate-specific antigen level above 20, high-grade disease (a Gleason score of 8 or more), and stage T3 disease (indicating the tumor has spread through the prostate), carries with it a poor prognosis.
Standard hormonal therapy, which stops the production of male hormones (androgens), has not been shown to be effective in this type of cancer when given before surgery. Nor has the surgery, which removes the entire prostate.
Zytiga blocks production of testosterone, which can promote the growth of prostate cancer cells, but in a different way than established hormonal treatments. Click here to read about the full details on the new study.
This latest development is a welcoming one in the research for prostate cancer treatment. Although it is a preliminary research as at the time of writing, it is hoped that more investigations and proofs, the outcome would be validated.
Finally, if men are treated of early stage or localized prostate cancer, then the chances of the cancer to spread to other parts of the body would be minimized. This would also mean extension of life for the patient. Zytiga (Abiraterone) is known to help those with advanced prostate cancer get relieved, with the recent research; another usage for it is highly welcomed.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Localized Prostate Cancer Treatment – Robot Assisted Surgery Better Than Open Surgery
- Zytiga – New Prostate Cancer Drug From BTG
- New Miracle Drugs to Cure Prostate Cancer – Abiraterone